Becton, Dickinson and Company (NYSE:BDX) Board Declares Share Repurchase Plan

Becton, Dickinson and Company (NYSE:BDX) announced that its board has initiated a share buyback program on Tuesday, January 27th, RTT News reports. The company plans to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BDX shares. Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Royal Bank Of Canada upped their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Jefferies Financial Group increased their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Finally, Piper Sandler lifted their price objective on Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research note on Wednesday. Four analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $209.00.

Becton, Dickinson and Company Stock Down 0.8%

Shares of NYSE BDX opened at $201.81 on Thursday. The business has a 50-day moving average of $198.08 and a two-hundred day moving average of $190.98. The company has a market capitalization of $57.50 billion, a price-to-earnings ratio of 34.62, a price-to-earnings-growth ratio of 2.25 and a beta of 0.23. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Becton, Dickinson and Company News Summary

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board set the record date (Feb 5) and distribution/closing date (Feb 9) for the spin-off of BD’s Biosciences & Diagnostic Solutions business — a structural move that could unlock value for shareholders. BD Announces Record Date for the Spin-Off
• Positive Sentiment: Waters Corporation shareholders approved the combination with BD’s Biosciences & Diagnostic Solutions unit, clearing a key step toward the planned transaction that underpins the spin-off strategy. Waters Shareholders Approve Combination
• Positive Sentiment: Board declared a $1.05 quarterly dividend (payable Mar 31; record/ex-div Mar 10), supporting income-focused investors and signaling cash-return discipline. BD Board Declares Dividend, Authorizes Repurchases
• Positive Sentiment: Company authorized an additional $10 million in share repurchases and has completed ~$250 million of repurchases year-to-date, which can support EPS and signal management confidence (note: $10M is small vs. market cap). Board Authorizes Additional Repurchases
• Positive Sentiment: Launched BD Research Cloud 7.0 with AI-powered features for flow cytometry — product innovation that can drive competitive positioning in diagnostics and recurring software/service revenue over time. BDX Introduces BD Research Cloud 7.0
• Neutral Sentiment: BD will release quarterly earnings and host a management webcast — an upcoming catalyst that could cause short-term volatility depending on results vs. guidance. BD to Release Quarterly Earnings
• Neutral Sentiment: Analyst and media pieces highlight BDX as a long-term value name versus peers; useful for investor sentiment but not an immediate price mover. Why Becton Dickinson is a Top Value Stock
• Negative Sentiment: Insider activity: EVP Michael Feld sold 75 shares (~$15.2k) on Jan 26 — a very small reduction in holdings (0.45% of his stake) that is unlikely to materially affect investor view but may be cited by short-term traders. SEC Form 4 – Michael Feld Sale

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,680 shares of company stock valued at $539,848. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.